专家建议制定工作组：
廖玉华(华中科技大学同济医学院附属协和医院)
程 翔(华中科技大学同济医学院附属协和医院)
袁 璟(华中科技大学同济医学院附属协和医院)
王 华(北京医院)
张宇辉(中国医学科学院阜外医院)
廖梦阳(华中科技大学同济医学院附属协和医院)
唐婷婷(华中科技大学同济医学院附属协和医院)
余 淼(华中科技大学同济医学院附属协和医院)
专家组成员(以姓氏拼音排序)：
程 翔(华中科技大学同济医学院附属协和医院)
陈志坚(华中科技大学同济医学院附属协和医院)
陈新忠(华中科技大学同济医学院附属协和医院)
陈光志(华中科技大学同济医学院附属同济医院)
陈 娟(武汉市中心医院)
韩红彦(武汉科技大学附属天佑医院)
洪李锋(武汉市第五医院)
胡立群(武汉市第四医院)
蒋学俊(武汉大学人民医院)
雷玉华(恩施土家族苗族自治州中心医院)
李 彬(襄阳市中心医院)
李正在(仙桃市第一人民医院)
廖梦阳(华中科技大学同济医学院附属协和医院)
廖玉华(华中科技大学同济医学院附属协和医院)
刘 红(洪湖市人民医院)
唐婷婷(华中科技大学同济医学院附属协和医院)
万 静(武汉大学中南医院)
汪朝晖(华中科技大学同济医学院附属协和医院)
王 华(北京医院)
王丽岳(武汉市武昌医院)
王杨淦(武汉大学中南医院)
王志权(中国人民解放军中部战区总医院)
余 淼(华中科技大学同济医学院附属协和医院)
袁 璟(华中科技大学同济医学院附属协和医院)
张友恩(十堰市人民医院)
张宇辉(中国医学科学院阜外医院)
周 恒(襄阳市第一人民医院)
周子华(华中科技大学同济医学院附属协和医院)
曾秋棠(华中科技大学同济医学院附属协和医院)
Expert recommendations on the management of common etiologies and comorbidities of heart failure in the primary hospitals
-
摘要: 心力衰竭是我国基层医院慢病管理的重要内容，其病因与合并症的及时处理可改善患者预后。本文依据近年心力衰竭治疗进展，对基层医院常见心力衰竭病因与合并症(包括心血管疾病和非心血管疾病两大类)临床治疗内容予以更新，并对及时向上级医院转诊提出专家建议，指导基层医师临床实践。Abstract: Heart failure is a significant component of chronic disease management in primary hospitals in China. Timely treatment of its etiology and comorbidities can improve patient outcomes. This article updates the management of common causes and comorbidities of heart failure in primary hospitals based on the recent progress in the treatment of heart failure, including cardiovascular and non-cardiovascular diseases. It also offers expert recommendations for timely referral to higher-level hospitals, thereby guiding primary care physicians in their clinical practice.
-
Key words:
- heart failure /
- primary hospital /
- etiology and comorbidities /
- treatment /
- referral
-
-
[1] Ambardekar AV, Thielen SC. Comorbidities in Heart Failure: Expect and Embrace the Complexity[J]. JACC Heart Fail, 2023, 11(11): 1504-1506. doi: 10.1016/j.jchf.2023.06.025
[2] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 中华慢性心力衰竭基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2019, 18(10): 936-947. doi: 10.3760/cma.j.issn.1671-7368.2019.10.008
[3] McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronicheart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726.
[4] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18): e895-e1032.
[5] 国家心血管病中心, 国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会, 等. 国家心力衰竭指南2023[J]. 中华心力衰竭和心肌病杂志. 2023, 7(4): 215-311. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202312011.htm
[6] Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2024, 149(1): e1-e156. doi: 10.1161/CIR.0000000000001208
[7] Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J, 2022, 43(40): 3997-4126.
[8] Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association(ERA)and the International Society of Hypertension(ISH)[J]. J Hypertens, 2023, 41(12): 1874-2071.
[9] Coisne A, Lancellotti P, Habib G, et al. ACC/AHA and ESC/EACTS Guidelines for the Management of Valvular Heart Diseases: JACC Guideline Comparison[J]. J Am Coll Cardiol, 2023, 82(8): 721-734. doi: 10.1016/j.jacc.2023.05.061
[10] Ammirati E, Frigerio M, Adler ED, et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document[J]. Circ Heart Fail, 2020, 13(11): e007405. doi: 10.1161/CIRCHEARTFAILURE.120.007405
[11] Seferović PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2019, 21(5): 553-576. doi: 10.1002/ejhf.1461
[12] Arbelo E, Protonotarios A, Gimeno JR, et al. ESC Scientific Document Group. 2023 ESC guidelines for the management of cardiomyopathies[J]. Eur Heart J, 2023, 44(37): 3503-3626.
[13] Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy[J]. Eur J Heart Fail, 2019, 21(7): 827-843. doi: 10.1002/ejhf.1493
[14] Menachem JN, Schlendorf KH, Mazurek JA, et al. Advanced Heart Failure in Adults With Congenital Heart Disease[J]. JACC Heart Fail, 2020, 8(2): 87-99.
[15] Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm-2023 Update[J]. Endocr Pract, 2023, 29(5): 305-340.
[16] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3): 221-255. https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL202311035.htm
[17] Damman K, Testani J. Cardiorenal interactions in heart failure-insights from recent therapeutic advances[J]. Cardiovasc Res, 2023.
[18] McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37): 3627-3639.
[19] Salah HM, Savarese G, Rosano G, et al. Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis[J]. ESC Heart Fail, 2023, 10(2): 1473-1480.
[20] Imran TF, Kurgansky KE, Patel YR, et al. Serial sodium values and adverse outcomes in heart failure with preserved ejection fraction[J]. Int J Cardiol, 2019, 290: 119-124.
[21] Suwanto D, Dewi IP, Fagi RA. Hyponatremia in heart failure: not just 135 to 145[J]. J Basic Clin Physiol Pharmacol, 2021, 33(4): 381-388.
[22] Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2020, 75(22): 2836-2850.
[23] Piani F, Agnoletti D, Borghi C. Advances in pharmacotherapies for hyperuricemia[J]. Expert Opin Pharmacother, 2023, 24(6): 737-745.
[24] Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association[J]. Circulation, 2021, 143(21): e984-e1010.
[25] Bielecka-Dabrowa A, Ebner N, Dos Santos MR, et al. Cachexia, muscle wasting, and frailty in cardiovascular disease[J]. Eur J Heart Fail, 2020, 22(12): 2314-2326.
-
下载:
图(1)
计量
- 文章访问数: 1837
- PDF下载数: 576
- 施引文献: 0